Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02977247Completed

Delphinus SoftVue Prospective Case Collection - ARM 2

Role: lead

NCT03257839Completed

Delphinus SoftVue Prospective Case Collection - ARM 1

Role: lead

NCT04260620Completed

Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)

Role: lead

NCT03698942Completed

Delphinus SoftVue™ ROC Reader Study

Role: lead

NCT03972605Completed

Delphinus SoftVue™ ROC Reader Study

Role: lead

All 5 trials loaded